| Year |
Citation |
Score |
| 2023 |
Rodriguez-Monguio R, Seoane-Vazquez E, Powers JH. A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas. Healthcare (Basel, Switzerland). 11. PMID 37372877 DOI: 10.3390/healthcare11121759 |
0.301 |
|
| 2023 |
Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare (Basel, Switzerland). 11. PMID 36833091 DOI: 10.3390/healthcare11040558 |
0.371 |
|
| 2023 |
Pham C, Le K, Draves M, Seoane-Vazquez E. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020. Jama Internal Medicine. PMID 36780147 DOI: 10.1001/jamainternmed.2022.6787 |
0.326 |
|
| 2021 |
Araujo L, Seoane-Vazquez E, Montagne M. Effect of free trade agreements on pharmaceutical market competition: The case of the 2009 US-Peru free trade agreement and its implementation as national drug policy. Health Policy Open. 2: 100039. PMID 37383506 DOI: 10.1016/j.hpopen.2021.100039 |
0.338 |
|
| 2020 |
Ghanem B, Althobaiti H, Phillipe G, Rodriguez-Monguio R, Seoane-Vazquez E. PDG38 ASSESSMENT OF GENERIC COMPETITION FOR ORPHAN DRUGS MARKETED IN THE US (1993-2019) Value in Health. 23: S136. DOI: 10.1016/j.jval.2020.04.326 |
0.3 |
|
| 2019 |
Shukla V, Seoane-Vazquez E, Fawaz S, Brown LM, Rodriguez-Monguio R. The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations. Human Gene Therapy. Clinical Development. PMID 30968714 DOI: 10.1089/Humc.2018.201 |
0.359 |
|
| 2018 |
Zeukeng M, Seoane-Vazquez E, Bonnabry P. Response to the letter to the Editor regarding Zeukeng et al.'s article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. European Journal of Clinical Pharmacology. 74: 1199-1200. PMID 29802425 DOI: 10.1007/S00228-018-2486-5 |
0.386 |
|
| 2018 |
Zeukeng M, Seoane-Vazquez E, Bonnabry P. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. European Journal of Clinical Pharmacology. 74: 811-818. PMID 29470610 DOI: 10.1007/S00228-018-2431-7 |
0.46 |
|
| 2018 |
Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. Bmc Health Services Research. 18: 78. PMID 29391064 DOI: 10.1186/S12913-018-2860-0 |
0.361 |
|
| 2018 |
Almutairi R, Seoane-Vazquez E, Rodriguez-Monguio R. PRM262 - TRENDS IN DRUG PRICES BEFORE AND AFTER GENERIC COMPETITION IN THE US (2014-2016) Value in Health. 21: S401. DOI: 10.1016/J.JVAL.2018.09.2379 |
0.34 |
|
| 2017 |
Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication Journal of the Saudi Pharmaceutical Society. 26: 238-243. PMID 30166922 DOI: 10.1016/J.Jsps.2017.12.005 |
0.403 |
|
| 2017 |
Seoane-Vazquez E, Rodriguez-Monguio R, Alqahtani S, Schiff G. Exploring the Potential for Using Drug Indications to Prevent Look-Alike and Sound-Alike Drug Errors. Expert Opinion On Drug Safety. PMID 28724335 DOI: 10.1080/14740338.2017.1358361 |
0.456 |
|
| 2017 |
Hansen RA, Qian J, Berg R, Linneman J, Seoane-Vazquez E, Dutcher SK, Raofi S, David Page C, Peissig P. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. Pharmacotherapy. PMID 28152215 DOI: 10.1002/Phar.1908 |
0.331 |
|
| 2017 |
Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet Journal of Rare Diseases. 12: 1-8. PMID 28057032 DOI: 10.1186/S13023-016-0551-7 |
0.466 |
|
| 2017 |
Zeukeng M, Seoane-Vazquez E. Comparison Of Food And Drug Administration, European Medicine Agency And Swissmedic New Drug Approval: An Assessment Of The International Harmonization Value in Health. 20: A657. DOI: 10.1016/j.jval.2017.08.1566 |
0.336 |
|
| 2016 |
Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. FDA safety actions for antidiabetic drugs marketed in the US, 1980-2015. The International Journal of Risk & Safety in Medicine. 28: 197-211. PMID 28582876 DOI: 10.3233/Jrs-170734 |
0.385 |
|
| 2016 |
Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. Osteoporosis Drugs Marketed In The United States: Generic Competition, Pricing Structure, And Dispersion Among Payers. International Journal of Technology Assessment in Health Care. 32: 385-392. PMID 28065194 DOI: 10.1017/S0266462316000623 |
0.452 |
|
| 2016 |
Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Current Medical Research and Opinion. 32: 1783-1788. PMID 27359262 DOI: 10.1080/03007995.2016.1208644 |
0.383 |
|
| 2016 |
Alsheikh M, Seoane-Vazquez E, Rittenhouse B, Fox ER, Fanikos J. A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hospital Pharmacy. 51: 370-5. PMID 27303090 DOI: 10.1310/Hpj5105-370 |
0.394 |
|
| 2016 |
Seoane-Vazquez E, Rodriguez-Monguio R, Alqahtani S. Response to letter to the editor regarding Alqahtani et al. Article on priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiology and Drug Safety. 25: 745-6. PMID 27245860 DOI: 10.1002/Pds.4010 |
0.327 |
|
| 2016 |
Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. Medicaid osteoporosis drugs utilization and expenditures: the effect of generic drugs market entry Journal of Pharmaceutical Health Services Research. 7: 217-224. DOI: 10.1111/Jphs.12144 |
0.47 |
|
| 2016 |
Alasmari MS, Seoane-Vazquez E, Rodriguez-Monguio, Eguale T, Szeinbach S. A Comparison of Cardiovascular Drugs Approved by the Us Food and Drug Administration and Health Canada (1980-2014) Value in Health. 19. DOI: 10.1016/J.Jval.2016.03.154 |
0.308 |
|
| 2016 |
Kaabi A, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach S, Heath N, Eguale T. A Comparison Of Antidepressant Drugs Approved By The Us Food And Drug Adminstration And Health Canada (1959-2015) Value in Health. 19. DOI: 10.1016/J.Jval.2016.03.1350 |
0.312 |
|
| 2016 |
Thumar R, Seoane-Vazquez E, Mantus D, Tyrrell B. ANALYSIS OF THE ULTRA-ORPHAN DRUGS APPROVED BY THE FDA IN THE PERIOD 1983-2014 Value in Health. 19: A255. DOI: 10.1016/J.JVAL.2016.03.1019 |
0.34 |
|
| 2016 |
Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs Clinical Drug Investigation. 1-12. DOI: 10.1007/S40261-015-0374-7 |
0.394 |
|
| 2015 |
Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. Plos One. 10: e0140708. PMID 26469277 DOI: 10.1371/Journal.Pone.0140708 |
0.409 |
|
| 2015 |
Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 1-8. PMID 26174631 DOI: 10.1586/14737167.2015.1068690 |
0.422 |
|
| 2015 |
Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiology and Drug Safety. 24: 709-15. PMID 26013294 DOI: 10.1002/Pds.3793 |
0.445 |
|
| 2015 |
Zeukeng M, Seoane-Vazquez E, Szeinbach S. Assessing the availability of Drugs marketed in the US and Switzerland Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.460 |
0.31 |
|
| 2015 |
Alqahtani SS, Rodriguez-Monguio R, Seoane-Vazquez E, Eguale T, Zeukeng MJ, Szeinbach S. Tracking the sponsoring Country of incorporation for new Drugs approved by the us FDA in the period 1980-2014: a trend analysis Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.420 |
0.309 |
|
| 2015 |
Alhawwashi ST, Alshahrani AM, Alsahali SM, Alasmari MS, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL. Trends in Approvals of New Drugs with Orphan Designation in the us (1983-2014) Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1760 |
0.404 |
|
| 2015 |
Alshehri A, Seoane-Vazquez E, Schneider T, Rodriguez-Monguio R. HIV Antiretroviral drug utilization and Expenditures In Medicaid 1991-2014 Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1425 |
0.324 |
|
| 2015 |
Briceno V, Seoane-Vazquez E. Analysis Of Nice Drug Technology Appraisals (2001-September 2014) Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.059 |
0.38 |
|
| 2014 |
Rodriguez-Monguio R, Spielberger K, Seoane-Vazquez E. Examination of risk evaluation and mitigation strategies and drug safety in the US. Research in Social & Administrative Pharmacy. 10: 232-238. PMID 23611865 DOI: 10.1016/J.Sapharm.2013.03.005 |
0.454 |
|
| 2014 |
Greene N, Turkistani F, Seoane-Vazquez E, Rodriguez-Monguio R. Trends in Approvals and Prices of Oncology Drugs in the United States (1990-2013) Value in Health. 17: A81. DOI: 10.1016/J.JVAL.2014.03.475 |
0.31 |
|
| 2014 |
Alshehri N, Alqahatani S, Alghamdi A, Alharbi A, Al-Mutairi R, Alotaibi A, Alshahrani A, Alsumali A, Badawoud E, Bin Sawad A, Turkistani F, Seoane-Vazquez E, Rodriguez-Monguio R. Analysis Of Average Manufacturer Prices Of New Drugs Approved In The United States (1990-2012) Value in Health. 17: A18-A19. DOI: 10.1016/J.JVAL.2014.03.117 |
0.329 |
|
| 2013 |
Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009 Journal of Law Medicine & Ethics. 41: 688-696. PMID 24088160 DOI: 10.1111/Jlme.12079 |
0.413 |
|
| 2013 |
Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies Bmc Health Services Research. 13: 27-27. PMID 23339419 DOI: 10.1186/1472-6963-13-27 |
0.403 |
|
| 2013 |
Balkhi B, Araujo-Lama L, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Fox ER. Shortages of systemic antibiotics in the USA: how long can we wait? Journal of Pharmaceutical Health Services Research. 4: 13-17. DOI: 10.1111/Jphs.12006 |
0.366 |
|
| 2013 |
Turkistani FA, Greene N, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL. Approvals And Market Discontinuations Of Oncology Drugs In The United States (1980-2012) Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.744 |
0.409 |
|
| 2013 |
Alshehri N, Seoane-Vazquez E, Rodriguez-Monguio R. A Comparison Of New Drugs Approved By The EMA and the FDA in 2006–2011 Value in Health. 16: A246. DOI: 10.1016/J.JVAL.2013.03.1251 |
0.335 |
|
| 2012 |
Visaria J, Seoane-Vazquez E, Szeinbach SL, Rodriguez-Monguio R. Comparing the cost of community pharmacy and mail-order pharmacy in a US retirement system. The International Journal of Health Planning and Management. 27: e41-50. PMID 21638311 DOI: 10.1002/Hpm.1089 |
0.343 |
|
| 2011 |
Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiology and Drug Safety. 20: 772-7. PMID 21574210 DOI: 10.1002/Pds.2155 |
0.376 |
|
| 2011 |
Le P, Seoane-Vazquez E, Rodriguez-Monguio R, Fox ER, Szeinbach SL, Dunehew AR, Montagne M. The prevalence of pharmaceutical shortages in the United States Journal of Generic Medicines. 8: 210-218. DOI: 10.1177/1741134311428105 |
0.374 |
|
| 2010 |
Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 18-24. PMID 19807903 DOI: 10.1111/J.1524-4733.2009.00604.X |
0.385 |
|
| 2009 |
Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Beyer A, Visaria J. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents. Food and Drug Law Journal. 64: 171-81. PMID 19998745 |
0.327 |
|
| 2009 |
Rodriguez-Monguio R, Seoane-Vazquez E. Patent life of antiretroviral drugs approved in the US from 1987 to 2007. Aids Care-Psychological and Socio-Medical Aspects of Aids\/Hiv. 21: 760-768. PMID 19499381 DOI: 10.1080/09540120802511950 |
0.418 |
|
| 2009 |
Qureshi Z, Szeinbach S, Seoane-Vazquez E, Rodriguez-Monguio R. Php16 Market Discontinuation Of Pharmaceuticals In The United States: Analysis Of Drugs Approved By The Fda From 1939 To 2008 Value in Health. 12. DOI: 10.1016/S1098-3015(10)73469-0 |
0.321 |
|
| 2008 |
Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases. 3: 33. PMID 19087348 DOI: 10.1186/1750-1172-3-33 |
0.452 |
|
| 2008 |
Seoane-Vazquez E, Rodriguez-Monguio R. Access to essential drugs in Guyana: a public health challenge International Journal of Health Planning and Management. 25: 2-16. PMID 18536003 DOI: 10.1002/Hpm.949 |
0.422 |
|
| 2008 |
Seoane-Vazquez EC, Schondelmeyer SW, Szeinbach SL. Drug patent live and generic competition: Analysis of new molecular entities approved by the FDA between 1980 and 1999 Journal of Pharmaceutical Finance, Economics & Policy. 16: 67-85. DOI: 10.1080/15385690801963530 |
0.66 |
|
| 2008 |
Rodriguez-Monguio R, Visaria J, Seoane-Vazquez E. Hp4 25Years Ofthe Orphan Drug Act:Analysis Ofthe New Orphan Drugsapproved Between 1983 And 2007 Value in Health. 11. DOI: 10.1016/S1098-3015(10)70051-6 |
0.419 |
|
| 2008 |
Oureshi Z, Szeinbach S, Seoane-Vazquez E. DH4 MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF NEW DRUGS APPROVED FROM 1980 TO 2007 Value in Health. 11: A5. DOI: 10.1016/S1098-3015(10)70032-2 |
0.325 |
|
| 2008 |
Seoane-Vazquez E, Rodriguez-Monguio R. HP1 ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007 Value in Health. 11: A359-A360. DOI: 10.1016/S1098-3015(10)66236-5 |
0.302 |
|
| 2007 |
Valluri S, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy. Bmc Health Services Research. 7: 122. PMID 17663768 DOI: 10.1186/1472-6963-7-122 |
0.401 |
|
| 2007 |
Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J, Carlson A. Endoscopy-related infections and toxic reactions: an international comparison. Endoscopy. 39: 742-778. PMID 17583855 DOI: 10.1055/S-2007-966504 |
0.308 |
|
| 2007 |
Seoane-Vazquez E, Rodriguez-Monguio R. Negotiating antiretroviral drug prices: the experience of the Andean countries Health Policy and Planning. 22: 63-72. PMID 17299024 DOI: 10.1093/Heapol/Czl039 |
0.358 |
|
| 2007 |
Rodríguez-Monguió R, Rovira J, Seoane-Vázquez E. Analysis of the World Bank's pharmaceutical lending. Health Policy. 81: 102-116. PMID 16824640 DOI: 10.1016/J.Healthpol.2006.05.016 |
0.335 |
|
| 2007 |
Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J. Php9 The Impact Of Mail Order Pharmacy In Drug Utilization And Reimbursement In A Large Retirement System Value in Health. 10. DOI: 10.1016/S1098-3015(10)68606-8 |
0.421 |
|
| Show low-probability matches. |